Pronto Diagnostics to Distribute Vermillion's OVA Test in Israel, Palestinian Territories
August 03, 2011
Pronto Diagnostics to Distribute Vermillion's OVA Test in Israel, Palestinian Territories
Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Vermillion's Q4 Revenues Increase 152 Percent on OVA1 Sales
March 27, 2012 / GenomeWeb Daily News - Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps
March 6, 2012 / GenomeWeb Daily News - Vermillion Shares Soar on Positive OVA1, Imaging Data
September 14, 2011 / GenomeWeb Daily News - Vermillion Reports OVA1 Tests Performed in 2010 Exceeds Guidance
January 5, 2011 / GenomeWeb Daily News - Vermillion Sends Quest Notice of Default Alleging Breach of Strategic Alliance Agreement
May 24, 2013 / ProteoMonitor